During the past decade, Studienzentrum Aschaffenburg conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 7 clinical trials were completed, i.e. on average, 41.2% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Studienzentrum Aschaffenburg" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "University of Heidelberg Medical Center" with 2 trials sponsored, "CTI BioPharma" with 1 trials sponsored and "Celgene" with 1 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Studienzentrum Aschaffenburg" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "DexCom, Inc. a Delaware corporation, USA" with 1 trials as a collaborator, "German CLL Study Group" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Studienzentrum Aschaffenburg" are "Diabetes Mellitus, Type 2" (3 trials), "Breast Cancer" (2 trials), "Diabetes Mellitus, Type 1" (2 trials), "Multiple Myeloma" (2 trials) and "Advanced Solid Tumors or Hematologic Malignancies" (1 trials). Many other conditions were trialed in "Studienzentrum Aschaffenburg" in a lesser frequency.

Most popular intervention types in "Studienzentrum Aschaffenburg" are "Drug" (19 trials), "Device" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Lenalidomide" (3 trials), "Atezolizumab" (2 trials), "Bortezomib" (2 trials) and "Dexamethasone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Studienzentrum Aschaffenburg" are 22 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Studienzentrum Aschaffenburg". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Studienzentrum Aschaffenburg, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Studienzentrum Aschaffenburg, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".